EGFR Mutation and Expression in Prostate Cancer
Author Information
Author(s): Peraldo-Neia Caterina, Migliardi Giorgia, Mello-Grand Maurizia, Montemurro Filippo, Segir Raffaella, Pignochino Ymera, Cavalloni Giuliana, Torchio Bruno, Mosso Luciano, Chiorino Giovanna, Aglietta Massimo
Primary Institution: Department of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy
Hypothesis
Accurate definition of the EGFR status could improve prognostic stratification and suggest a possible role for EGFR-directed therapies in prostate cancer patients.
Conclusion
EGFR overexpression is significantly associated with biochemical relapse in prostate cancer patients.
Supporting Evidence
- 36% of tumor samples showed EGFR protein overexpression.
- 13% of samples had mutations in the EGFR TK domain.
- Patients with EGFRhigh tumors had a significantly increased risk of biochemical relapse.
Takeaway
This study looked at how a protein called EGFR behaves in prostate cancer. They found that when there's too much of this protein, it can mean the cancer is more likely to come back.
Methodology
EGFR mutation analysis and immunohistochemistry were performed on tumor tissues from 100 prostate cancer patients, with gene expression profiling conducted on 51 samples.
Limitations
The study had a small sample size and was limited to an Italian population, which may affect the generalizability of the results.
Participant Demographics
Patients were of Italian origin, median age 66 years.
Statistical Information
P-Value
0.02
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website